Literature DB >> 10739378

Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults.

B Voetsch1, B P Damasceno, E C Camargo, A Massaro, L A Bacheschi, M Scaff, J M Annichino-Bizzacchi, V R Arruda.   

Abstract

INTRODUCTION: Several recent studies have analyzed a possible effect of thrombophilia risk factors such as factor V Leiden, the prothrombin variant (allele 20210 A), and homozygosity for thermolabile methylenetetrahydrofolate reductase (MTHFR-T) on the development of ischemic stroke (IS). In the present study, we determined the role of these prothrombotic polymorphisms in the early onset of arterial IS or cerebral venous thrombosis (CVT) in a group of young Brazilian adults of Caucasian and African descent.
MATERIALS AND METHODS: We conducted a cross-sectional study of 167 survivors of IS (153 patients with arterial IS and 14 cases of CVT; 66 men: 101 women; 124 of Caucasian and 43 of African origin; median age: 32.6 years; range: 15 to 45 years) and compared the prevalence of inherited thrombophilia risk factors with a control group of 225 sex and age matched individuals of the same ethnic background. To determine the interaction with atherogenic risk factors, the following diagnoses were considered: hypertension, hyperlipoproteinemia, diabetes mellitus, smoking status and use of oral contraceptives.
RESULTS: In the arterial IS group, no significant variation was found between patients and controls of Caucasian origin regarding the prevalence of factor V Leiden (P = 0.92), the prothrombin variant (P = 0.13) or homozygosity for MTHFR-T (P = 0.61). Among Brazilians of African descent, 10.3% were homozygous for MTHFR-T, which was significantly elevated, odds ratio of 5.9 (95% CI: 0.88 to 49.15). In the CVT group, two Caucasian patients (20%) were heterozygous for the prothrombin variant, odds ratio of 9.7 (95% CI: 0.95 to 89.71) and one patient was carrier of factor V Leiden (P = 0.49). No prothrombotic polymorphism was identified in patients with CVT of African descent. All women in the CVT group were in use of oral contraceptives or in the post-partum state. DISCUSSION: Inherited thrombophilia risk factors were not found to increase the risk of arterial IS among young patients of Caucasian descent. However, a potential role of homozygosity for MTHFR-T was observed in a small group of patients of African origin. The analysis of patients with CVT revealed an increased risk due to the prothrombin gene variant or oral contraceptive use. Further studies including all incoming patients with IS are necessary to evaluate the impact of inherited thrombophilia risk factors on early mortality.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739378

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  22 in total

1.  Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease.

Authors:  Adriano Sabino; Ana Paula Fernandes; Luciana Moreira Lima; Daniel Dias Ribeiro; Marinez Oliveira Sousa; Maria Elizabeth Rennó de Castro Santos; Ana Paula Lucas Mota; Luci Maria Sant'Ana Dusse; Maria das Graças Carvalho
Journal:  J Thromb Thrombolysis       Date:  2007-11-27       Impact factor: 2.300

Review 2.  Haematology and neurology.

Authors:  Steven Austin; Hannah Cohen; Nick Losseff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04       Impact factor: 10.154

3.  The G79A polymorphism of protein Z gene is an independent risk factor for cerebral venous thrombosis.

Authors:  V Le Cam-Duchez; A Bagan-Triquenot; V Barbay; B Mihout; J Y Borg
Journal:  J Neurol       Date:  2008-07-31       Impact factor: 4.849

4.  Human platelet alloantigens HPA-1, HPA-2, and HPA-3 polymorphisms associated with extent of severe coronary artery disease.

Authors:  Nesrine Abboud; Lakdhar Ghazouani; Sonia Ben-Hadj-Khalifa; Fatma Anabi; Faouzi Added; Ali Khalfallah; Brahim Nsiri; Wassim Y Almawi; Touhami Mahjoub
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

5.  Prothrombin G20210A and factor V Leiden polymorphisms in stroke.

Authors:  Thierry Paluku They-They; Omar Battas; Ilham Slassi; Mohamed Abdou Rafai; Desire Tshala Katumbay; Sellama Nadifi
Journal:  J Mol Neurosci       Date:  2011-06-24       Impact factor: 3.444

6.  Prothrombin G20210A mutation is associated with young-onset stroke: the genetics of early-onset stroke study and meta-analysis.

Authors:  Baijia Jiang; Kathleen A Ryan; Ali Hamedani; Yuching Cheng; Mary J Sparks; Deborah Koontz; Christopher J Bean; Margaret Gallagher; W Craig Hooper; Patrick F McArdle; Jeffrey R O'Connell; O Colin Stine; Marcella A Wozniak; Barney J Stern; Braxton D Mitchell; Steven J Kittner; John W Cole
Journal:  Stroke       Date:  2014-03-11       Impact factor: 7.914

7.  Factor V leiden and ischemic stroke risk: the Genetics of Early Onset Stroke (GEOS) study.

Authors:  Ali G Hamedani; John W Cole; Yuching Cheng; Mary J Sparks; Jeffrey R O'Connell; Oscar C Stine; Marcella A Wozniak; Barney J Stern; Braxton D Mitchell; Steven J Kittner
Journal:  J Stroke Cerebrovasc Dis       Date:  2011-11-18       Impact factor: 2.136

8.  Do hospital doctors test for thrombophilia in patients with venous thromboembolism?

Authors:  Daryoush Samim; Pedro Marques-Vidal; Lorenzo Alberio; Gérard Waeber; Marie Méan
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

9.  Meta-analysis of factor V Leiden and ischemic stroke in young adults: the importance of case ascertainment.

Authors:  Ali G Hamedani; John W Cole; Braxton D Mitchell; Steven J Kittner
Journal:  Stroke       Date:  2010-07-08       Impact factor: 7.914

10.  Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease.

Authors:  Wassim Y Almawi; Ghada Ameen; Hala Tamim; Ramzi R Finan; Noha Irani-Hakime
Journal:  J Thromb Thrombolysis       Date:  2004-06       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.